Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORY-MDS/MPN
NCT05600894Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2023
- Primary completion
- Aug 2027
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax in chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by National Cancer Institute. Started Jun 2023; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05600894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600894.